Abstract: The invention relates to a process for producing cultured red blood cells from stem cells or cells of an immortalized cell line of the erythroid lineage.

Abstract: The present invention relates to a process for the in vitro production of erythroid progenitors comprising contacting hematopoietic stem cells, genetically modified or not, with a defined cell culture medium comprising a glucocorticoid hormone and an autophagy inducer.

Abstract: The present invention relates to a method of preparing hematopoietic cell graft or enriching a population of cells for hematopoietic stem cells that are capable of long-term multilineage engraftment and self-renewal. It also relates to hematopoietic grafts comprising said hematopoietic stem cells as well as their uses in therapy.

Abstract: The present invention relates to a capsule comprising at least one cell with hematopoietic potential, said capsule being formed with a liquid core and at least one gelled shell encapsulating totally the liquid core at its periphery, to the use of such a capsule for producing ex vivo enucleated erythroid cells as well as an ex vivo method for producing enucleated erythroid cells using said capsule.

Abstract: A method for the production of cells of the hematopoietic lineage includes culturing hematopoietic stem cells (HSC) or embryonic bodies with a cell culture medium (the cell culture medium includes insulin at a concentration of from 1 to 50 ?g/ml, transferrin at a concentration of from 100 ?g/ml to 2000 ?g/ml and plasma or serum at a concentration of from 1% to 30%) under conditions allowing producing cells of the hematopoietic lineage; and collecting cells of the hematopoietic lineage.

Abstract: The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

Abstract: The present invention relates to a cell culture medium for the growth and/or differentiation of cells of the hematopoietic lineage, comprising: —insulin at a concentration of from 1 to 50 ?g/ml; —transferrin at a concentration of from 100 ?g/ml to 2000 ?g/ml; and—plasma or serum at a concentration of from 1% to 30%.

Abstract: The invention relates to a method for the expansion and differentiation of haematopoietic stem cells into enucleated erythrocytes, in two steps: a first step in a culture medium, where cell proliferation and erythmid differentiation are induced in the presence of growth factors, and a second step modeling a reconstitution of the microenvironment, substantially without erythropoietin (EPO). Optionally, the method of culture may comprise an intermediate step, with haematopoietic growth factors.

Abstract: The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

Abstract: The invention relates to a method for the expansion and differentiation of haematopoietic stem cells into enucleated erythrocytes, in two steps: a first step in a culture medium, where cell proliferation and erythroid differentiation are induced in the presence of growth factors, and a second step modeling a reconstitution of the microenvironment, substantially without erythropoietin (EPO). Optionally, the method of culture may comprise an intermediate step, with haematopoietic growth factors.

Abstract: A cell growth method and device with multiple applications, in particular to the maintenance, proliferation, amplification or differentiation of cells in a closed enclosure (10), including individual flow rate or quantity adjustment means (30, 36) for determining compositions and flow rates of mixtures of different nutrient media or constituents and compositions and flow rates of different mixtures of growth factors, corresponding to an envisaged application, and then to modify the compositions and/or the flow rates of the mixtures of nutrient media or constituents and of the mixtures of growth factors delivered to the enclosure, which modifications can be effected independently of each other.